Synthes Bone Void Filler Off-Label Concerns, MDR Gaps Elicit FDA Warning
This article was originally published in The Gray Sheet
Executive Summary
Synthes should have secured an investigational device exemption before soliciting information from physicians on patient experiences with the firm's Norian XR calcium phosphate bone void filler, according to a recent FDA warning letter